Tag: partnerships

The Europe defibrillator market, valued at USD 3.87 billion in 2024, is projected to reach USD 7.23 billion by 2033, with a CAGR of 7.2%. Growth drivers include rising cardiovascular diseases, technological advancements, and government initiatives to expand public defibrillator access. Key segments include implantable and external defibrillators with significant usage in hospitals, public, and home settings. The market faces challenges such as high device costs and regulatory complexities. Leading players like Medtronic and Philips are instrumental in market expansion through innovations and strategic partnerships across Europe.

Zurich, July 29, 2025 – MetrioPharm AG, a pharmaceutical company developing drugs for inflammatory and infectious diseases, announced today that the European Medicines Agency has granted Orphan Drug Designation (ODD) to its lead compound, MP1032 for the treatment of children affected by Duchenne muscular dystrophy (DMD). This milestone follows the U.S. FDA's ODD, underscoring MP1032's potential as a first-in-class therapy that could minimize reliance on high-dose corticosteroids, which cause severe side effects like osteoporosis, growth stunting, and metabolic issues.

Key Highlights: